This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Medidata Nearly Doubles Usage Of Its Clinical Trial Management System In Year Since Acquisition

Stocks in this article: MDSO

During the first year of offering Medidata CTMS™, an innovative cloud-based clinical trial management system, Medidata Solutions (NASDAQ: MDSO) dramatically expanded its CTMS customer base and is launching a major product enhancement—a seamless integration of Medidata CTMS with Medidata Rave ®, a leading electronic data capture (EDC) and clinical data management system (CDMS).

With the integration, Medidata offers customers a single, out-of-the-box solution for EDC, CDM and CTM that can streamline their clinical operations in an easy-to-deploy, cloud-based platform. The CTMS was acquired by Medidata through its acquisition of Clinical Force in July 2011, and since then the number of active studies running on the platform has grown by more than 85 percent.

“Medidata CTMS fulfills our customers’ need for an innovative, scalable solution that brings the same type of efficiencies to clinical operations as the rest of the Medidata Clinical Cloud,” said Glen de Vries, president, Medidata Solutions. “Given that we continue to enhance Medidata CTMS’ functionality—most recently releasing an upgrade that seamlessly integrates with Medidata Rave—it is no surprise that the number of studies actively running on the platform has nearly doubled over the past year.”

The integration between Medidata CTMS and Rave increases the efficiency of study monitors and clinical research associates. Data is automatically pulled from Rave into Medidata CTMS monitor reports, limiting room for errors and cutting out redundancies in data entry, contributing to time savings and improved data quality. With an increase in the number of study monitors actively using the system today—in fact, 60 percent more compared to just one year ago—the new out-of-the-box integration translates into significant aggregate time savings for life science companies.

To support increased customer usage of this enhanced product, Medidata now offers its customers an eLearning course, Medidata CTMS for Monitors, which provides instruction on best practices for site monitoring tasks, as part of the Medidata University product training program.

Connect with Medidata:

About Medidata Solutions Worldwide

Medidata Solutions is a leading global provider of cloud-based clinical development solutions that enhance the efficiency of customers’ clinical trials. Medidata’s advanced platform lowers the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.

Copyright Business Wire 2010

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs